Phase II study of bortezomib, thalidomide, and dexamethasone /- cyclophosphamide as induction therapy in previously untreated multiple myeloma (MM): safety and activity including evaluation of MRD

• Authors: LUDWIG H.; VITERBO L.; GREIL R.; ŠPIČKA Ivan; HÁJEK Roman; DMOSZYNSKA A.; PAIVA B.; VIDRIALES M.; ESTEVES G.; STOPPA A.; RICCI D.; CAKANA A.; ENNY C.; FENG H.; VAN DE VELDE H.; HAROUSSEAU JL.
• Year of publication: 2010
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: VTD and VTDC are both highly active induction regimens, resulting in high CR rates and MRD-negative rates. Depth of response improved post-HDT-ASCT. Although efficacy profiles were similar, rates of toxicity were higher with VTDC than VTD.